Date: 2015-04-20
Type of information: Commercialisation agreement
Compound: X-MAN human haploid and diploid isogenic cell line collection
Company: Horizon Discovery (UK) Thermo Fisher Scientific (USA - MA)
Therapeutic area: Technology - Services
Type agreement: supply commercialisation
Action mechanism: The X-MAN cell line range represents an extensive bank of genetically defined human cell lines - models that accurately exhibit disease-causing genetics, and have undergone a high degree of validation and quality control. These models help researchers to understand how complex genetic diseases manifest themselves, and can reduce the cost of bringing to market new personalized therapies by streamlining many aspects of drug development, including target identification, target validation, assay development, drug screening, lead optimization and biomarker-driven clinical trial design.
Disease:
Details: * On April 20, 2015, Horizon Discovery, the international life science company supplying research tools and services that power genomics research and the development of personalized medicines, announced it has signed a supply and commercialisation agreement with Thermo Fisher Scientific, the world leader in serving science. Under the terms of the agreement, Thermo Fisher will market and distribute Horizon\'s X-MAN human haploid and diploid isogenic cell line collection and will further offer Horizon\'s X-MAN haploid cell line generation service to its worldwide customer base. The X-MAN catalogue includes both diploid (cells with two natural copies of each gene) cell lines and haploid (proprietary cells engineered to have only one copy of each gene) cell lines developed using Horizon\'s proprietary precision (rAAV) and high-throughput (HT-CRISPR) genome-editing technologies. Additionally, Horizon offers rapid and low cost on-demand generation of engineered haploid cell lines that for the first time bring these valuable research tools to the 72,000+ research labs studying the basic and applied function of genes and genetic variation.
Financial terms:
Latest news:
